30 June 2011 Business
Industry news, July 2011
Hormonally-driven cancer drug discovery specialist Aragon Pharmaceuticals has been bought by Johnson & Johnson. The deal covers Aragon’s androgen receptor antagonist programme, including an advanced drug candidate for prostate cancer.
Androgen has spun out the rest of the company to form Seragon Pharmaceuticals, which will develop breast cancer drugs that work by degrading oestrogen receptors.
J&J paid $650 million (£417 million) up front, and will pay up to $350 million more if various milestones are reached. The androgen receptor antagonist programme will be managed by J&J’s subsidiary Janssen.
1 June 2012 Carousel
Sergio Bertazzo / Thomas von Erlach / Imperial College London
20 February 2014 Comments
Fracking won’t plug the gap in crude oil’s falling figures, says Chris Rhodes. Oil’s exhaustion is inevitable
11 March 2014 Research
Asteroid impact could have produced enough sulfur trioxide to dramatically lower ocean pH